

## NEWS RELEASE

### **iX Biopharma Unveils Novel NAD Wafers at the Centre for Healthy Longevity Conference 2024**

- ✓ Scientific research suggests NAD supplementation may combat age-related decline, reduce the risk of chronic diseases like diabetes and heart disease and protect muscle health
- ✓ Utilising iX Biopharma's NADiX delivery technology, the novel pure NAD freeze-dried sublingual wafers offer a direct method of supplementing NAD levels, marking a significant advancement compared to supplementation with NAD precursors
- ✓ The NAD wafers meet the rising demand for anti-aging solutions in rapidly aging developed economies like Singapore and China

**Singapore, 4 March 2024** – iX Biopharma Ltd (“**iX Biopharma**” or the “**Company**”), a specialty pharmaceutical company specialising in drug delivery systems, showcased its groundbreaking NAD (nicotinamide adenine dinucleotide) wafers at the prestigious Centre for Healthy Longevity Conference 2024 held in Singapore on 29 February to 1 March 2024.

This event, which focused on the role of supplements in unlocking healthy longevity, brought together an esteemed cohort of leading scientists, including Professors Andrea Maier and Brian Kennedy of the NUHS Centre for Healthy Longevity, and Professor David Sinclair of the Harvard Medical School. Other expert clinicians, key opinion leaders, industry partners, consumer representatives, and regulatory authorities deeply involved in longevity and healthspan research were also present.

At the conference, iX Biopharma introduced its pioneering sublingual NAD wafers, leveraging the revolutionary NADiX technology to deliver pure NAD nanoparticles directly into the body without the need for otherwise invasive intravenous infusions. The feedback from the experts and participants was overwhelmingly positive, with many expressing excitement at NADiX being able to overcome challenges in delivering NAD to the body and the potential for the sublingual NAD wafers to be a game-changer in improving healthspan.

The Company's showcase is timely and coincides with the announcement made by the State Council of the People's Republic of China (“**PRC**”) in January 2024, in which the PRC government called on companies to better cater to the elderly and to promote the “silver economy” through measures including health products. The Company intends to engage with potential partners and stakeholders in China and to that end, it will be exhibiting at the Wuhan Health Expo in April 2024, where an anticipated 300,000 participants will be attending.

---

Eva Tan, Chief Commercial Officer of iX Biopharma, said: “By pioneering innovative supplements like our sublingual NAD wafers, iX Biopharma is demonstrating its commitment to healthspan innovation, empowering individuals to optimise their health and longevity. Supplements are crucial for effective healthcare, especially in aging prevention. NAD can make up for lifestyle factors that speed up aging, and by taking NAD, people can potentially avoid age-related health problems and live longer, healthier lives, boosting their energy and well-being as they grow older.”

### **About iX Biopharma Ltd**

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of using novel, patent-protected formulations for sublingual delivery.

iX Biopharma has developed a number of patented drug delivery platform technologies, including WaferiX, WaferlogiX and NADiX, which deliver small molecule and biologics sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The drug delivery platforms are particularly useful for drug repurposing, where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk. iX Biopharma’s portfolio includes among others, ketamine, dexmedetomidine, sublingual vaccine delivery, and healthspan products.

---

#### Contact for media:

Eva Tan  
Chief Commercial Officer  
T: +65 6235 3212  
E: [eva.tan@ixbiopharma.com](mailto:eva.tan@ixbiopharma.com)

Alvina Tan  
Media & Investor Relations Consultant  
T: +65 9787 7267  
E: [alvina.tan@arkadvisors.com.sg](mailto:alvina.tan@arkadvisors.com.sg)